It is widely recognized that genetic medicines have the potential to transform the treatments of a variety of debilitating diseases. However, the fundamental challenge remains in finding a way to deliver genetic medicines to the targeted cells in vivo. Couragene was founded to address this challenge head-on by developing a suite of first-in-class delivery platforms.

We are innovators and pioneers who aspire to address the most significant unmet medical needs.

Amy Liao, PhD
Co-Founder and Chief Executive Officer, Couragene